New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 31, 2014
05:45 EDTMYGN, AETAetna BRCA testing policy bulletin not a change, says William Blair
William Blair says shares of Myriad Genetics (MYGN) dropped 2% Friday after Aetna (AET) issued a clinical policy bulletin update for BRCA testing that changed the word "Myriad" to "Laboratory." The firm believes the bulletin does not represent a change to the status quo since a number of labs now offer BRCA testing. William Blair keeps an Outperform rating on Myriad.
News For MYGN;AET From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
December 19, 2014
12:12 EDTMYGNMyriad Genetics receives FDA approval of BRACAnalysis CDx
Myriad Genetics (MYGN) announced that it has received approval from the U.S. FDA for BRACAnalysis CDx to be used as the only companion diagnostic in conjunction with AstraZeneca's (AZN) drug Lynparza. Lynparza is the first poly ADP-ribose polymerase inhibitor for patients with germline mutations in BRCA1/2 advanced ovarian cancer who have had three or more lines of chemotherapy. BRACAnalysis CDx is Myriad's first FDA-approved companion diagnostic for use with a novel PARP inhibitor. BRACAnalysis CDx is a highly accurate molecular companion diagnostic test that identifies deleterious or suspected deleterious mutations in the BRCA1 and BRCA2 genes, using DNA obtained from a blood sample. BRACAnalysis CDx was proven in clinical studies to effectively identify patients with BRCA mutations who would be candidates for Lynparza. The approval of BRACAnalysis CDx demonstrates Myriad's commitment to developing companion diagnostics and is the culmination of an intensive, multiyear scientific collaboration with AstraZeneca to advance personalized medicine for women with ovarian cancer.
10:17 EDTMYGNOn The Fly: Analyst Initiation Summary
Subscribe for More Information
07:15 EDTMYGNMyriad Genetics initiated with a Market Perform at Wells Fargo
Subscribe for More Information
December 17, 2014
10:51 EDTAETLeerink healthcare services analyst holds analyst/industry conference call
Healthcare Services Analyst Gupte provides outlook and favorite names for 2015 in the Hospitals and Managed Care Industry on an Analyst/Industry conference call to be held on December 18 at 1 pm.
10:21 EDTMYGNMyriad denied appeal to block competing breast cancer tests, Bloombeg reports
Subscribe for More Information
December 12, 2014
13:52 EDTAETLeerink healthcare services analyst holds an analyst/industry conference call
Subscribe for More Information
08:46 EDTAETAetna price target raised to $103 from $92 at Credit Suisse
Credit Suisse raised Outperform rated Aetna's price target to $103 based on updated guidance and longer term growth opportunities.
08:03 EDTAETAetna 2015 EPS guidance cautious, says Wells Fargo
Subscribe for More Information
December 11, 2014
12:54 EDTMYGNMyriad Genetics management to meet with William Blair
Subscribe for More Information
08:50 EDTAETAetna sees operating EPS highest in 1Q15
Subscribe for More Information
December 10, 2014
17:04 EDTAETAetna sees FY15 operating EPS at least $6.90, consensus $7.17
Sees FY15 operating revenue at least $62B, consensus $61.68B. Guidance to be confirmed at investor conference in New York on December 11.
17:02 EDTAETAetna backs FY14 operating EPS $6.60-$6.70, consensus $6.68
Subscribe for More Information
14:45 EDTAETDeal would block payments to health insurance companies, The Hill says
Subscribe for More Information
December 9, 2014
14:22 EDTAETAetna updates clinical policy for H.P. Acthar Gel
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use